In individuals with familial LCAT deficiency, where the ability to esterify cholesterol in HDL is impaired, recombinant LCAT and small molecules enhancing LCAT activity may be future therapeutic options [87–89]. Here, LCAT is linked to hyperinsulinemic hypoglycemia, familial, 4.